Bioequivalence Study of Progesterone Vaginal Insert 100 mg in Healthy Pre-Menopausal, Nonpregnant Female Subjects.

The primary objective of this study is to evaluate the **bioequivalence** of a 100 mg **progesterone vaginal insert** in healthy pre-menopausal, nonpregnant female subjects. This assessment is clinically relevant as it determines whether the vaginal insert delivers the same therapeutic effect and safety profile as an existing approved product, ensuring consistent efficacy and safety for users. No secondary objectives are specified for this study.

The clinical trial involves a study population consisting exclusively of **female** participants, with an age range categorized as "3," which typically corresponds to a specific age group as defined by the study protocol. The trial does not focus on any specific **medical condition**, as indicated by the absence of a defined medical condition for the participants. The sponsor has not provided information regarding the total number of participants involved in the trial. The trial population selection criteria include a focus on a **vulnerable population**, although specific details regarding the nature of this vulnerability are not disclosed. Lifestyle considerations such as diet, physical activity, or habits are not specified in the available data. The sponsor has not provided detailed inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate the **bioequivalence** of a progesterone vaginal insert at a dosage of 100 mg in healthy pre-menopausal, nonpregnant female subjects. This study is a Phase 2 trial, which is categorized as a controlled trial. The trial is expected to commence recruitment on August 26, 2023, and is anticipated to conclude by October 31, 2023. The trial does not involve any specific medical condition, as it targets healthy individuals.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. During this visit, eligibility criteria will be assessed to ensure that participants meet the necessary requirements for inclusion in the study. Following successful screening, participants will be enrolled in the trial and will attend scheduled follow-up visits. These visits are designed to monitor the participants' health and the effects of the progesterone vaginal insert. The sequence and frequency of these visits will be determined by the study protocol, ensuring comprehensive data collection and participant safety.

The end-of-study visit marks the conclusion of the participant's involvement in the trial. This visit will include final assessments to evaluate the outcomes of the treatment and to ensure the well-being of the participants. The expected length of participant involvement will be determined by the study protocol, which will outline the duration of treatment and follow-up periods. Conditions that may lead to early termination from the study include adverse reactions to the treatment, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is structured to maintain the integrity of the data collected while prioritizing participant safety and adherence to ethical standards.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial may focus solely on the experimental medication, but further information would be required to confirm this aspect.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on August 26, 2023, with an estimated end date of October 31, 2023. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the therapeutic impact of the intervention under investigation, adhering to the rigorous standards expected in clinical research. The trial's design and execution will align with the objectives typical of a Phase 2 study, which generally aims to explore the efficacy and optimal dosing of the treatment. The absence of specific endpoints in the provided data suggests that these will be determined according to standard clinical trial practices and regulatory guidelines.